Abstract
The combined procedures of lymphatic mapping and sentinel lymph node biopsy (SLNB) have been devised as minimally invasive alternatives to elective lymph node dissection to identify occult metastases in patients with clinically node-negative localized primary invasive cutaneous melanoma (CM) and who might benefit from therapeutic lymph node dissection (TLND).1,2 An international randomized cohort study of patients with primary CM of intermediate thickness, the Multicenter Selective Lymphadenectomy Trial (MSLT),3 was designed to determine the survival impact of lymphatic mapping plus SLNB (and immediate TLND for positive cases), compared with nodal observation. According to this study,3 there was no significant difference in disease-specific survival when the 2 groups were compared. Retrospective studies by other groups have shown similar results.4-8

This publication has 57 references indexed in Scilit: